VeroScience LLC
Records under this name other than the patents VeroScience LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 36 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,655,865 | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes Lapsed on the fee record Ended May 23, 2025 · From the USPTO record | Lapsed on the fee record | Ended May 23, 2025 | From the USPTO record |
| US 7,888,310 | Methods of identifying responders to dopamine agonist therapy Term ended Ended no later than Mar 22, 2025 · From the USPTO record | Term ended | Ended no later than Mar 22, 2025 | From the USPTO record |
| US 8,821,915 | Therapeutic Process for the Treatment of the Metabolic Syndrome and Associated Metabolic Disorders Term ended Term ended Aug 6, 2023 · High confidence | Term ended | Term ended Aug 6, 2023 | High confidence |
| US 9,364,515 | Therapeutic Process For The Treatment Of The Metabolic Syndrome And Associated Metabolic Disorders Term ended Term ended Aug 6, 2023 · High confidence | Term ended | Term ended Aug 6, 2023 | High confidence |
| US 9,999,653 | Therapeutic Process For The Treatment Of The Metabolic Syndrome And Associated Metabolic Disorders Term ended Term ended Aug 6, 2023 · High confidence | Term ended | Term ended Aug 6, 2023 | High confidence |
| US 8,137,992 | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof Term ended Ended no later than Feb 28, 2022 · From the USPTO record | Term ended | Ended no later than Feb 28, 2022 | From the USPTO record |
| US 8,137,993 | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof Term ended Ended no later than Feb 28, 2022 · From the USPTO record | Term ended | Ended no later than Feb 28, 2022 | From the USPTO record |
| US 8,137,994 | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof Term ended Ended no later than Feb 28, 2022 · From the USPTO record | Term ended | Ended no later than Feb 28, 2022 | From the USPTO record |
| US 6,855,707 | Method for the treatment of lipid and glucose metabolism disorders Term ended Term ended Apr 28, 2017 · From the USPTO record | Term ended | Term ended Apr 28, 2017 | From the USPTO record |
| US 6,071,914 | Method for inhibiting neoplastic disease in mammals Term ended Term ended May 31, 2016 · From the USPTO record | Term ended | Term ended May 31, 2016 | From the USPTO record |